# Glycemic Variability of Combination Therapies in T2DM

Study · id `cardio:ct-nct07442006` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07442006](<https://clinicaltrials.gov/study/NCT07442006>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07442006

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 178 participants.

## Technical summary

Registry record NCT07442006. Randomized; no masking; primary purpose treatment. Start 2025-10-29 (actual); primary completion 2027-03-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 178 participants (planned count; ClinicalTrials.gov record NCT07442006, source copy `cardio:ctgov-nct07442006-2026-03-02`, retrieved 2026-10-26)
- Started: 2025-10-29 (actual) (ClinicalTrials.gov record NCT07442006, source copy `cardio:ctgov-nct07442006-2026-03-02`, retrieved 2026-10-26)
- Primary completion: 2027-03-31 (anticipated) (ClinicalTrials.gov record NCT07442006, source copy `cardio:ctgov-nct07442006-2026-03-02`, retrieved 2026-10-26)
- Completion: 2027-03-31 (anticipated) (ClinicalTrials.gov record NCT07442006, source copy `cardio:ctgov-nct07442006-2026-03-02`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT07442006, source copy `cardio:ctgov-nct07442006-2026-03-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07442006-2026-03-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glycemic Variability of Combination Therapies in T2DM
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): Empagliflozin/Metformin
- Intervention (Drug): Anagliptin
- Intervention (Drug): Metformin
- Intervention (Drug): Empagliflozin/Linagliptin
- Lead sponsor: JW Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: JW Pharmaceutical (`cardio:org-jw-pharmaceutical`)

## Provenance

Content hash: 43a5600a6814ebff8c2798615befc3d071877c770cb78f340b7350ab4cccefa0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
